<div id="readability-page-1"><p>Farther Finance Advisors LLC boosted its position in shares of  Cencora, Inc. (NYSE:COR - Free Report) by 107.4% in the 2nd quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 4,512 shares of the company's stock after buying an additional 2,337 shares during the quarter. Farther Finance Advisors LLC's holdings in Cencora were worth $1,353,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p><ul><li>Top 3 S&amp;P 500 Winners in a Losing Market</li></ul><p>Several other institutional investors and hedge funds also recently bought and sold shares of the company. Net Worth Advisory Group boosted its stake in  Cencora by 1.4% during the first quarter. Net Worth Advisory Group now owns 2,645 shares of the company's stock worth $736,000 after buying an additional 36 shares during the period.  Obermeyer Wealth Partners boosted its stake in  Cencora by 1.3% during the first quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company's stock worth $758,000 after buying an additional 36 shares during the period.  Grove Bank &amp; Trust boosted its stake in  Cencora by 4.3% during the second quarter. Grove Bank &amp; Trust now owns 879 shares of the company's stock worth $264,000 after buying an additional 36 shares during the period.  Cromwell Holdings LLC boosted its stake in  Cencora by 9.5% during the first quarter. Cromwell Holdings LLC now owns 450 shares of the company's stock worth $125,000 after buying an additional 39 shares during the period.  Finally, Contravisory Investment Management Inc. boosted its stake in  Cencora by 0.7% during the second quarter. Contravisory Investment Management Inc. now owns 5,382 shares of the company's stock worth $1,614,000 after buying an additional 40 shares during the period. 97.52% of the stock is owned by hedge funds and other institutional investors. </p><h2>Analysts Set New Price Targets</h2><p>A number of analysts have recently issued reports on COR shares. Morgan Stanley  set a $330.00 target price on shares of Cencora and gave the company an &#34;equal weight&#34; rating in a research note on Wednesday, July 16th. Jefferies Financial Group boosted their target price on shares of Cencora from $275.00 to $300.00 and gave the company a &#34;hold&#34; rating in a research note on Monday, June 30th. Finally, Wells Fargo &amp; Company boosted their target price on shares of Cencora from $337.00 to $354.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, August 13th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock  has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $311.25.</p><ul><li>Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy</li></ul><p><b>Check Out Our Latest Analysis on Cencora</b></p><h2>Insider Activity</h2><p>In other news, Chairman Steven H. Collis sold 31,350 shares of the company's stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the company's stock in a transaction dated Thursday, September 18th. The shares were sold at an average price of $290.00, for a total transaction of $1,478,130.00. Following the transaction, the chief executive officer owned 39,274 shares in the company, valued at approximately $11,389,460. This trade represents a 11.49% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 55,993 shares of company stock worth $16,292,923. Corporate insiders own  10.80% of the company's stock. </p><h2>Cencora Stock Performance</h2><ul><li>Teva Pharma is the way to play the re-rise of generic drugs </li></ul><p>Shares of Cencora stock opened at $301.95 on Wednesday. The company has a market capitalization of $58.54 billion, a PE ratio of 31.06, a P/E/G ratio of 1.47 and a beta of 0.62. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The company has a 50-day simple moving average of $292.41 and a two-hundred day simple moving average of $287.63. Cencora, Inc. has a one year low of $218.65 and a one year high of $309.35. </p><p>Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, topping analysts' consensus estimates of $3.79 by $0.21. The business had revenue of $80.66 billion during the quarter, compared to the consensus estimate of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm's revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the company posted $3.34 earnings per share.  Research analysts expect that  Cencora, Inc. will post 15.37 EPS for the current fiscal year. </p><h2>Cencora Dividend Announcement</h2><p>The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, August 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.7%. Cencora's dividend payout ratio  is 22.63%. </p><h2>Cencora Company Profile</h2> (Free Report)<p>Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.</p><h2>See Also</h2><ul><li>Five stocks we like better than Cencora</li><li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li><li>3 Quantum Computing ETFs to Know—And Why 2 Don't Hold D-Wave</li><li>Stock Market Upgrades: What Are They?</li><li>Forget Tariffs, Landstar and West Fraser Can Still Rally </li><li>What is the Nikkei 225 index?    </li><li>Is Super Micro Next in Line for a Big AI Takeover?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cencora Right Now?</h2><p>Before you consider Cencora, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.</p><p>While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Farther Finance Advisors LLC increased its stake in Cencora, Inc. (NYSE:COR) by 107.4% in Q2, acquiring an additional 2,337 shares, bringing its total to 4,512 shares valued at $1.35 million. Other institutional investors also raised their stakes. Analysts have set a consensus price target of $311.25 for Cencora, with a "Moderate Buy" rating. Recent insider sales included Chairman Steven H. Collis and CEO Robert P. Mauch, who sold significant shares. Cencora's stock opened at $301.95, with a market cap of $58.54 billion and a PE ratio of 31.06.</p>

Farther Finance Advisors LLC Acquires 2,337 Shares of Cencora, Inc. $COR